Objective response seen in 37.1 percent of patients with previously treated KRAS p.G12C-mutated non-small cell lung cancer<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, June 9, 2021 (HealthDay News) — Sotorasib therapy yields clinical benefit for patients with previously treated KRAS<\/em> p.G12C-mutated non-small cell lung cancer (NSCLC), according to a study published online June 4 in the New England Journal of Medicine <\/em>to coincide with the annual meeting of the American Society of Clinical Oncology, held virtually from June 4 to 8.<\/p>\n Ferdinandos Skoulidis, M.D., Ph.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted a single-group, phase 2 trial to examine the activity of sotorasib, administered orally once daily in 124 patients with KRAS<\/em> p.G12C-mutated advanced NSCLC previously treated with standard therapies. The primary end point was objective response (complete or partial).<\/p>\n The researchers found that 46 patients (37.1 percent) had an objective response, including four and 42 who had a complete and partial response, respectively; the median response duration was 11.1 months. One hundred of the patients had disease control. The median progression-free survival and median overall survival were 6.8 and 12.5 months, respectively. Treatment-related adverse events occurred in 69.8 percent of patients, including grade 3 and 4 events in 19.8 and 0.8 percent, respectively. In subgroups defined according to programmed death ligand-1 expression, tumor mutational burden, and co-occurring mutations in STK11<\/em>, KEAP1<\/em>, or TP53<\/em>, responses were observed.<\/p>\n “This trial provides convincing evidence that mutant KRAS<\/em> can be successfully and selectively targeted, resulting in meaningful prolongation of survival without compromising quality of life,” Skoulidis said in a statement.<\/p>\n Several authors disclosed financial ties to biopharmaceutical companies, including Amgen, which manufactures sotorasib and funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n